Payload Information
General Information of This Payload
| Payload ID | PAY0ERPRD |
|||||
|---|---|---|---|---|---|---|
| Name | US12209180B2 AM2 |
|||||
| Synonyms |
AM2
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
AbA_D265C_LALA_H435A-AM2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
280 pM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro BM HSC killing assay: ADCs conjugated to AM2
|
||||
| In Vitro Model | Bone marrow hematopoietic stem cells | BM HSC cells (CD34+CD90+) | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.0005 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.0008 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.0173 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.033 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM3, or PBD
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.12 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.16 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM2, or PBD
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.42 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.538 nM
|
Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) |
0.6071 nM
|
Positive CD45 expression (CD45+++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SKNO-1 cells | CVCL_2196 | ||